SECURITY AGREEMENT (Patent)
Contract Categories:
Business Finance
- Security Agreements
EX-10.4 7 ex10-4.htm ex10-4.htm
Exhibit 10.4
SECURITY AGREEMENT
(Patent)
THIS SECURITY AGREEMENT (PATENT) (“Agreement”), is entered into and made effective as of January 3, 2008, by and between IR BIOSCIENCES HOLDINGS, INC., a Delaware corporation with its principal place of business located at 8767 E. Via De Ventura, Suite 190, Scottsdale, AZ 85258 (the “Parent”), and the each subsidiary of the Parent listed on Schedule I attached hereto (each a “Subsidiary,” and collectively and together with the Parent, the “Company”), in favor of the YA GLOBAL INVESTMENTS, L.P. (the “Secured Party”).
WITNESETH:
WHEREAS, in connection with the Securities Purchase Agreement by and among the Parent and the Secured Party of even date herewith (the “Securities Purchase Agreement”), the Parent has agreed, upon the terms and subject to the conditions of the Securities Purchase Agreement, to issue to the Secured Party (i) an aggregate original principal amount of up to $3,000,000 of senior secured convertible debentures (the “Convertible Debentures”), which shall be convertible into shares of the Parent’s Common Stock (the “Conversion Shares”); and (ii) warrants (the “Warrants”) to be exercisable to acquire additional shares of Common Stock (the “Warrants Shares”) initially in that number of shares of Common Stock set forth in the Securities Purchase Agreement;
WHEREAS, to induce the Secured Party to purchase the Convertible Debentures and enter into the Securities Purchase Agreement and the documents entered into in connection therewith, (collectively referred to as the “Transaction Documents”), each Company hereby grants to the Secured Party a security interest, in and to the Patent Collateral (as defined below) to secure all of the Obligations (as defined below).
WHEREAS, in connection with the Securities Purchase Agreement, each Company has agreed to provide the Secured Party a general security interest in the Pledged Property (as this term is defined in the Security Agreement by and between each Company and the Secured Party, dated January 3, 2008 (together with all amendments, supplements, restatements and other modifications, if any, from time to time made thereto, the “Security Agreement”);
WHEREAS, each Company has duly authorized the execution, delivery and performance of this Agreement;
NOW THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, the Company agrees as follows:
SECTION 1. Definitions. Unless otherwise defined herein otherwise requires, terms used in this Agreement, including its preamble and recitals, have the meanings provided in the Securities Purchase Agreement.
(a) “Obligations” shall have the meaning assigned to it in the Security Agreement.
SECTION 2. Grant of Security Interest. For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, to secure the payment and performance of all of the Obligations of the Company, the Company does hereby mortgage, pledge and hypothecate to the Secured Party and grant to the Secured Party a security interest in all of the following property (the “Patent Collateral”), now owned and existing:
(a) all letters patent and applications for letters patent throughout the world, including all patent applications in preparation for filing anywhere in the world and including each patent and patent application referred to in Schedule A hereto;
(b) all reissues, divisions, continuations, continuations-in-part, extensions, renewals and reexaminations of any of the items described in clause (a);
(c) all patent licenses and other agreements providing the Company with the right to use any of the items of the type referred to in clauses (a) and (b), including each patent license referred to in Schedule A hereto;
(d) the right to sue third parties for past, present or future infringements of any Patent Collateral described in clauses (a) and (b) and, to the extent applicable, clause (c); and
(e) all proceeds of, and rights associated with, the foregoing, (including license royalties and proceeds of infringement suits), and all rights corresponding thereto throughout the world.
SECTION 3. Security Agreement. This Agreement has been executed and delivered by each Company for the purpose of recording the security interest of the Secured Party in the Patent Collateral relating to patents referred to in Schedule A with the United States Patent and Trade Marks Office, to the extent it may be so registered therein. The security interest granted hereby has been granted as a supplement to, and not in limitation of, the security interest granted to the Secured Party under the Security Agreement. The Security Agreement (and all rights and remedies of the Secured Party thereunder) shall remain in full force and effect in accordance with its terms.
SECTION 4. Release of Security Interest. Upon payment in full of all Obligations the Secured Party shall, at the Company’s expense, execute and deliver to the Company all instruments and other documents as may be necessary or proper to release the lien on any security interest in the Patent Collateral which has been granted hereunder.
SECTION 5. Acknowledgement. The Company does hereby further acknowledge and affirm that the rights and remedies of the Secured Party with respect to the security interest in the Patent Collateral granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which (including the remedies provided for therein) are incorporated by references herein as if fully set forth herein.
SECTION 6. Securities Purchase Agreement. Notwithstanding any other term or provision hereof, in the event that any provisions hereof contradict and are incapable of being construed in conjunction with the provisions of the Securities Purchase Agreement, the provisions of the Securities Purchase Agreement shall take precedence over those contained herein and, in particular, if any act of the Company is expressly permitted under the Securities Purchase Agreement but is prohibited hereunder, any such act shall be permitted hereunder and any encumbrance expressly permitted under the Securities Purchase Agreement to exist or to remain outstanding shall be permitted hereunder and thereunder. This instrument, document or agreement may be sold, assigned or transferred by the Agent in accordance with the terms of the Securities Purchase Agreement.
SECTION 7. Counterparts. This Agreement may be executed by the parties hereto in several counterparts, each of which shall be deemed to be an original and all of which shall constitute together but one and the same agreement.
IN WITNESS WHEREOF, the parties hereto have executed this Security Agreement as of the date first above written
IR Biosciences Holdings, Inc. | |
By: /s/ Michael Wilhelm | |
Name: Michael Wilhelm | |
Title: President and Chief Executive Officer | |
STATE OF ____________________)
) SS:
COUNTY OF __________________)
BEFORE ME, a Notary Public in and for said County and State, personally appeared the above-named Michael Wilhelm who acknowledged that he/she did sign the foregoing agreement and that the same is his/her free act and deed.
IN TESTIMONY WHEREOF, I have hereunto set my hand an official seal at __________________, ____________________, this ___ day of __________, 2007.
/s/ Michelle R. Laroche | |
Notary Public |
IN WITNESS WHEREOF, the parties hereto have executed this Security Agreement as of the date first above written.
COMPANY: | |
ImmuneRegen BioSciences, Inc. | |
By: /s/ Michael Wilhelm | |
Name: Michael Wilhelm | |
Title: President and Chief Executive Officer | |
STATE OF ____________________)
) SS:
COUNTY OF __________________)
BEFORE ME, a Notary Public in and for said County and State, personally appeared the above-named Michael Wilhelm who acknowledged that he/she did sign the foregoing agreement and that the same is his/her free act and deed.
IN TESTIMONY WHEREOF, I have hereunto set my hand an official seal at __________________, ____________________, this ___ day of __________, 2007.
/s/ Michelle R. Laroche | |
Notary Public |
IN WITNESS WHEREOF, the parties hereto have executed this Security Agreement as of the date first above written.
SECURED PARTY: | |
YA GLOBAL INVESTMENTS, L.P. | |
By: Yorkville Advisors, LLC | |
Its: Investment Manager | |
By: /s/ Mark Angelo | |
Name: Mark Angelo | |
Title: Portfolio Manager | |
SCHEDULE I
LEGAL NAMES; ORGANIZATIONAL IDENTIFICATION NUMBERS; STATES OF ORGANIZATION
Company’s Name | State of Organization | Employer ID | Organizational ID |
IR Biosciences Holdings, Inc. | Delaware | 13 ###-###-#### | |
ImmuneRegen BioSciences, Inc. | Delaware | 11 ###-###-#### |
SCHEDULE A
US PATENTS AND APPLICATIONS
TITLE | COUNTRY | FILING DATE | APPLICATION NUMBER | DATE ISSUED | PATENT NUMBER |
Substance P Treatment for Immunostimulation | United States of America | 23-Feb-98 | 09/028003 | 7-Dec-99 | 5998376 |
Substance P Treatment for Immunostimulation | United States of America | 28-Mar-97 | 08/829445 | 31-Aug-99 | 5945508 |
Substance P Treatment for Immunostimulation | Australia | 8-Jul-97 | 40464/97 | 22-Nov-01 | 737201 |
Substance P Treatment for Immunostimulation | Canada | 8-Jul-97 | 2261885 | ||
Substance P Treatment for Immunostimulation | Switzerland | 8-Jul-97 | 97938049 | 24-Mar-04 | 957930 |
Substance P Treatment for Immunostimulation | Germany | 8-Jul-97 | 97938049 | 24-Mar-04 | 957930 |
Substance P Treatment for Immunostimulation | France | 8-Jul-97 | 97938049 | 24-Mar-04 | 957930 |
Substance P Treatment for Immunostimulation | Spain | 8-Jul-97 | 97938049 | 24-Mar-04 | 957930 |
Substance P Treatment for Immunostimulation | United Kingdom | 8-Jul-97 | 97938049 | 24-Mar-04 | 957930 |
Substance P Treatment for Immunostimulation | Ireland | 8-Jul-97 | 97938049 | 24-Mar-04 | 957930 |
Substance P Treatment for Immunostimulation | Italy | 8-Jul-97 | 97938049 | 24-Mar-04 | 957930 |
Substance P Treatment for Immunostimulation | Liechtenstein | 8-Jul-97 | 97938049 | 24-Mar-04 | 957930 |
Substance P Treatment for Immunostimulation | Monaco | 8-Jul-97 | 97938049 | 24-Mar-04 | 957930 |
Amelioration of Effects of Cigarette Smoke | United States of America | 22-Aug-03 | 10/645,839 | ||
Amelioration of Effects of Cigarette Smoke | Singapore | 22-Aug-03 | 200501072-3 | ||
Amelioration of Effects of Cigarette Smoke | China | 22-Aug-03 | 3820184.4 | ||
Amelioration of Effects of Cigarette Smoke | Japan | 22-Aug-03 | 2004-532943 | ||
Amelioration of Effects of Cigarette Smoke | European Patent Office | 22-Aug-03 | 3791722.6 | ||
Amelioration of Effects of Cigarette Smoke | Canada | 22-Aug-03 | 2496447 | ||
Amelioration of Effects of Cigarette Smoke | Vietnam | 22-Aug-03 | 1-2005-00215 | ||
Acute Respiratory Syndromes | Hong Kong | 22-Jun-06 | 6107144.4 | ||
Acute Respiratory Syndromes | European Patent Office | 14-Apr-04 | 4759500.4 | ||
Acute Respiratory Syndromes | United States of America | 14-Oct-05 | 10/553,232 | ||
Acute Respiratory Syndromes | Singapore | 14-Apr-04 | 200507608-8 | ||
Use of Substance P or its Analogs for the Manufacture of Medicaments for Treating or Protecting SARS or ARDS | Vietnam | 14-Apr-04 | 1-2005-01560 | ||
Prevention of Respiratory Infections in Fowl | European Patent Office | 23-Nov-05 | 5849894 | ||
Prevention of Respiratory Infections in Fowl | Singapore | 27-Jan-05 | 200500467-6 | ||
Prevention of Respiratory Infections in Fowl | Thailand | 11-Feb-05 | 97659 | ||
Prevention of Respiratory Infections in Fowl | Patent Cooperation Treaty | 23-Nov-05 | PCT/US05/42601 | ||
Prevention of Respiratory Infections in Fowl | United States of America | 3-July-07 | 11/795,044 | ||
Prevention of Respiratory Infections in Fowl | Australia | 23-Nov-05 | 2005323304 | ||
Prevention of Respiratory Infections in Fowl | Japan | 23-Nov-05 | 2007-549376 | ||
Prevention of Respiratory Infections in Fowl | Canada | 23-Nov-05 | 2,593,232 | ||
Prevention of Respiratory Infections in Fowl | Vietnam | 5-May-05 | 1-2005-00599 | ||
Treatment of Skin Diseases | European Patent Office | 15-Dec-05 | 5854144.2 | ||
Treatment of Skin Diseases | Singapore | 27-Jan-05 | 200500466-8 | ||
Treatment of Skin Diseases | Vietnam | 5-May-05 | 1-2005-00598 | ||
Treatment of Skin Diseases | Thailand | 25-Feb-05 | 98080 | ||
Treatment of Skin Diseases | Canada | 15-Dec-05 | 2594517 | ||
Treatment of Skin Diseases | Australia | 15-Dec-05 | 2005324417 | ||
Treatment of Skin Diseases | Patent Cooperation Treaty | 15-Dec-05 | PCT/US05/45369 | ||
Method to Promote Wound Healing | European Patent Office | 25-Oct-05 | 5813067.5 |
Method to Promote Wound Healing | Australia | 25-Oct-05 | 2005299341 | ||
Method to Promote Wound Healing | Japan | 25-Oct-05 | 2007-539081 | ||
Method to Promote Wound Healing | Canada | 25-Oct-05 | 2585265 | ||
Method to Promote Wound Healing | Patent Cooperation Treaty | 25-Oct-05 | PCT/US05/38646 | ||
Method to Promote Wound Healing | United States of America | 27-Apr-07 | 11/666,474 | ||
Treatment for Asthma | Patent Cooperation Treaty | 31-Mar-06 | PCT/US06/011833 | ||
Treatment for Asthma | European Patent Office | 31-Mar-06 | 6748998.9 | ||
Treatment for Asthma | Japan | 31-Mar-06 | tba | ||
Treatment for Asthma | Australia | 31-Mar-06 | tba | ||
Treatment for Asthma | Canada | 31-Mar-06 | tba | ||
Treatment for Asthma | Singapore | 24-Jun-05 | 200504104-1 | ||
Treatment for Asthma | United States of America | 25-Sep-07 | 11/887,105 | ||
Stimulation of Hair Growth | United States of America | 20-Jun-05 | 10/539,734 | ||
Stimulation of Hair Growth | Patent Cooperation Treaty | 18-Dec-03 | PCT/US03/40259 | ||
Inducing and Maintaining Hair Color | United States of America | 25-Oct-06 | 11/587,594 | ||
Inducing and Maintaining Hair Color | Patent Cooperation Treaty | 18-Apr-05 | PCT/US05/13112 | ||
Anti-Aging Effects of Substance P | Patent Cooperation Treaty | 18-Apr-05 | PCT/US05/13113 | ||
Anti-Aging Effects of Substance P | Japan | 18-Apr-05 | 2007-509540 | ||
Anti-Aging Effects of Substance P | Canada | 18-Apr-05 | tba | ||
Anti-Aging Effects of Substance P | United States of America | 25-Oct-06 | PCT/US05/13113 | ||
Anti-Aging Effects of Substance P | European Patent Office | 18-Apr-05 | 5755488.3 | ||
Anti-Aging Effects of Substance P | China | 18-Apr-05 | 2005-80016786.5 | ||
Anti-Aging Effects of Substance P | Australia | 18-Apr-05 | 2005240026 | ||
Method to Reduce the Risk and/or Severity of Anthrax Infection | Patent Cooperation Treaty | 6-Mar-07 | PCT/US07/05668 | ||
Method to Reduce the Risk and/or Severity of Anthrax Infection | United States of America | 2-Feb 07 | 60/889,035 | ||
Prophylactic and Therapeutic Treatment of Mammals for Avian InfluenzaVirus Infection | Patent Cooperation Treaty | 14-Aug-07 | PCT/US07/017953 | ||
Prophylactic and Therapeutic Treatment of Mammals for Avian InfluenzaVirus Infection | United States of America | 1-May-07 | 60/915,373 | ||
Prophylactic and Therapeutic Treatment of Mammals for Avian InfluenzaVirus Infection | United States of America | 15-Aug-06 | 60/837,635 | ||
Prophylactic and Therapeutic Treatment of Mammals for Avian InfluenzaVirus Infection | United States of America | 9-Oct-06 | 60/828,728 | ||
Prophylactic and Therapeutic Treatment of Mammals for Avian InfluenzaVirus Infection | United States of America | 22-Nov-06 | 60/866,901 | ||
Method to Treat Blood Cell Depletion | Patent Cooperation Treaty | 30-May-07 | PCT/US tba | ||
Method to Treat Blood Cell Depletion, In Conditions Such as MDS | United States of America | 27-Jul-07 | 60/952,394 | ||
Method to Stimulates Blood Cells Regeneration Following Non-Lethal Radiation Exposure | United States of America | 30-Jul-07 | 0/952,691 | ||
Substance P and Analogs Thereofas aVaccine Adjuvant | United States of America | 18-Jan-07 | 60/885,562 | ||
Substance P as an Adjuvant | United States of America | 14-Aug-07 | 60/955,712 | ||
Use of Homspera (substance P analog) as an Adjuvant | United States of America | 1-May-07 | 60/915,358 | ||
Methods of Using Substance P and Analogs for Ameliorating Adverse Effects of Drugs | United States of America | 20-Aug-07 | 60/965,580 | ||
Substance P Analogs as PARP Inhibitors | United States of America | 29-Aug-07 | 60/966,948 | ||
Substance P Analogs to Promote Cell Differentiation | United States of America | 2-Oct-07 | 60/997,314 | ||
Methods of Stimulating the Proliferation and/or Differentiation of Stem Cells withSubstance P, or an Analog | United States of America | 26-Oct-07 | 60/983,012 | ||
Substance P Analogs to Stimulate Fibroblast Growth | United States of America | 12-Oct-07 | 60/979,769 | ||
Methods and Compositions for Improving the Texture or Appearance of Skin with Substance P or an Analog Thereof | United States of America | 21-Dec-07 | 61/016,245 | ||
ELISA for Substance P Analogs | United States of America | tba |